Literature DB >> 2994557

In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of beta-lactams with clavulanic acid or sulbactam.

P Van der Auwera, B Scorneaux.   

Abstract

The in vitro susceptibility of human isolates of Campylobacter jejuni was investigated with 27 antibiotics and 8 combinations of beta-lactams with clavulanic acid or sulbactam. Ansamycin, the new quinolines, erythromycin, and cefpirome were the most active drugs against C. jejuni; amoxicillin, ampicillin, cefotaxime, and ceftazidime 90% of the isolates, greater than or equal to 50 mg/liter). The activity of various beta-lactams was unchanged by the addition of clavulanic acid or sulbactam.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2994557      PMCID： PMC176305          DOI： 10.1128/AAC.28.1.37

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Campylobacter jejuni post-transfusional septicaemia.

Authors:  F Pepersack; T Prigogyne; J P Butzler; E Yourassowsky
Journal:  Lancet       Date:  1979-10-27       Impact factor: 79.321

Review 2.  Campylobacter infections in human beings.

Authors:  P J Rettig
Journal:  J Pediatr       Date:  1979-06       Impact factor: 4.406

3.  Oxolinic acid metabolism by man.

Authors:  F J Dicarlo; M C Crw; M D Melgar; S Roemer; S M Ringel; L J Haynes; M Wilson
Journal:  Arch Int Pharmacodyn Ther       Date:  1968-08

4.  Intestinal antisepsis. Stability of fecal flora during mechanical cleansing.

Authors:  G H Bornside; I Cohn
Journal:  Gastroenterology       Date:  1969-11       Impact factor: 22.682

5.  Effect of erythromycin on the fecal excretion of Campylobacter fetus subspecies jejuni.

Authors:  T Pitkanen; T Pettersson; A Pomka; T U Kosunen
Journal:  J Infect Dis       Date:  1982-01       Impact factor: 5.226

6.  Susceptibility of Campylobacter fetus subsp. jejuni to twenty-nine antimicrobial agents.

Authors:  R Vanhoof; M P Vanderlinden; R Dierickx; S Lauwers; E Yourassowsky; J P Butzler
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

7.  Campylobacters isolated from hospital patients.

Authors:  P Cavanagh; A Ryden
Journal:  Med J Aust       Date:  1978-10-21       Impact factor: 7.738

8.  Susceptibility of Campylobacter fetus subsp. jejuni to twenty antimicrobiol agents.

Authors:  M Walder
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

9.  Trimethoprim-sulfamethoxazole therapy for shigellosis.

Authors:  J D Nelson; H Kusmiesz; L H Jackson; E Woodman
Journal:  JAMA       Date:  1976-03-22       Impact factor: 56.272

10.  Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone.

Authors:  H L DuPont; R R Reves; E Galindo; P S Sullivan; L V Wood; J G Mendiola
Journal:  N Engl J Med       Date:  1982-09-30       Impact factor: 91.245
View more
  15 in total

1.  In vitro activities of Ro 40-6890 against 164 predominantly intestinal members of the families Enterobacteriaceae and Vibrionaceae.

Authors:  P Hohl; J Zollinger-Iten; A von Graevenitz
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 2.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

3.  Effect of clavulanic acid on susceptibility of Campylobacter jejuni and Campylobacter coli to eight beta-lactam antibiotics.

Authors:  C L Gaudreau; L A Lariviere; J C Lauzer; F F Turgeon
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

Review 4.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

5.  Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.

Authors:  P Tajada; J L Gomez-Graces; J I Alós; D Balas; R Cogollos
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

6.  Role of the beta-lactamase of Campylobacter jejuni in resistance to beta-lactam agents.

Authors:  N Lachance; C Gaudreau; F Lamothe; L A Larivière
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

7.  Susceptibilities of fluoroquinolone-resistant strains of Campylobacter jejuni to 11 oral antimicrobial agents.

Authors:  J L Gomez-Garces; R Cogollos; J L Alos
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 8.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

Review 9.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

10.  Comparative in vitro activity of ceftibuten (Sch 39720) against bacterial enteropathogens.

Authors:  R Shawar; M LaRocco; T G Cleary
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.